Skip to main contentrtttttt Skip to main content
Integrative Psychiatry

MDMA in Support of Autistic Adults

All of us are wired for connection. Yet historically, the medical community has operated from a neurotypical perspective, often pathologizing neurodivergent folks such as those on the autism spectrum, particularly as it shows up in social settings. It is common for adults with autism to feel misunderstood and rely on masking to mirror neurotypical social scripts, the pressures of which can affect mental health and wellbeing. While there is still very limited research on the topic, few studies have shown potential for the use of MDMA to alleviate social anxiety and depression among autistic adults. In fact, MDMA may support a neurological “relearning” of social reward in the brain, creating a sense of safety and enjoyment in the social nervous system. As a person who identifies as neurotypical, it is important for me to name that I don’t see MDMA as a “treatment” for autism; rather, I want to uplift the growing community of autistic voices who describe healing for themselves through this medicine.

Supporting Mental Health

Autistic adults experience high rates of anxiety and depression, which may arise, in part, from cultural structures that are not designed to meet neurodivergent needs. For example, the challenges of navigating social interactions and sensory sensitivities might create tension, worry, burnout, and feelings of helplessness. MDMA-assisted therapy shows promise in reducing levels of anxiety and depression by facilitating emotional processing, regulating the nervous system, inspiring new perspectives about life experiences, and rewriting self narratives.

Feeling Connected

The social reward pathway involves the release of neurotransmitters like dopamine and oxytocin in response to interpersonal interactions, playing an important role in shaping behavior, feelings of connectedness, and motivation toward sociality. Emerging research suggests that MDMA acts on this area of the brain, with exciting implications for repatterning circuits toward relaxation and joy in social situations. By promoting feelings of empathy, trust, and emotional openness, MDMA may increase a sense of ease within the body, lending itself to supporting an individual in finding their desired levels of comfort in social situations and connection with others. 

Deepening Self-Awareness and Acceptance

Research thus far suggests that psychedelics enhance psychological flexibility and cognitive reappraisal (see more on psychedelics and self concept here). MDMA-assisted therapy invites an exploration of a person’s inner world, fostering self-compassion toward their strengths and challenges. Adults with autism have reported a deeper understanding of their thought processes after receiving MDMA-assisted therapy, expressing desires to explore their identities, relationships with themselves, and relationships with others.

Clinical Considerations and Future Directions

While the potential of MDMA-assisted therapy in autism is exciting, research is still limited and ongoing. In clinical practice, it will be important to develop inclusive protocols that meet the needs and sensitivities of autistic individuals, ensure adequate support and ethical engagement across neurodiversity spectra, provide effective integration following psychedelic experiences, and navigate the changing legal considerations for psychedelic-assisted therapy. Psychedelic-assisted therapy may not be for everyone, yet it holds potential to uplift neurodiverse communities, encouraging understanding, acceptance, and healing on an individual and social scale.

For more information, see 

https://www.autisticpsychedelic.com/

https://www.ndpsychedelic.com/

https://www.autismonacid.com/ 

Sara Reed, MS, LMFT

Sara Reed is a Licensed Marriage and Family Therapist and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. As a mental health futurist and clinical researcher, Sara examines the ways culture informs the way we diagnose and treat mental illness. Sara’s prior research work includes participation as a study therapist in psychedelic therapy research at Yale University and the University of Connecticut’s Health Center. Sara was the first Black therapist to provide MDMA-assisted psychotherapy in a clinical trial and continues to engage in ongoing advocacy work around health equity in psychedelic medicine.

https://psychiatryinstitute.com/wp-content/uploads/2019/11/Jeffrey-Guss.png

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psychedelic-assisted psychotherapy in the treatment of cancer-related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psychedelic-Assisted therapy in the treatment of Alcoholism, a collaborator with Yale University’s study on psychedelic-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS (Multidisciplinary Association for Psychedelic Studies) study on treatment of Post Traumatic Stress Disorder with Psychedelic-Assisted Psychotherapy. 

Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He has published (with Elizabeth Nielson, PhD) a paper on “the influence of therapists’ first had experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training” in The Journal of Psychedelic Studies, August, 2018. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies and Supervisor in NYU’s Fellowship in Addiction Psychiatry. 

Dr. Guss maintains a private practice in New York City.

Will Van Derveer, MD

Will Van Derveer, MD is Co-Founder of Integrative Psychiatry Institute and Integrative Psychiatry Centers. Dr. Van Derveer was co-investigator on a phase 2 MAPS study of Psychedelic-assisted psychotherapy for treatment-resistant PTSD, and co-authored the publication of this study in 2018. He has also provided Psychedelic-assisted psychotherapy in two MAPS training studies. An active provider of KAP at his clinic in Boulder, CO, he has been teaching others KAP therapy for several years. Dr. Van Derveer contributed a chapter on mescaline in the 2021 "Handbook of Medical Hallucinogens" (edited by Charles Grob and Jim Grigsby). He is co-host of the Higher Practice Podcast.

Dr. Van Derveer regards unresolved emotional trauma as the most significant under-recognized root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass.


Scott has been a student of consciousness since his honors thesis on that topic at the University of Arizona in the 1970s under the tutelage of Dr. Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. Psychedelic-assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.

In 2010 he founded Wholeness Center in Fort Collins. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principal Investigator and therapist for the Phase III trial of psychedelic-assisted psychotherapy for PTSD sponsored by (MAPS). He has also published numerous articles about his research on (CBD) in mental health. Currently, Scott works extensively with psychedelic-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools, and a paradigm-shifting perspective about transformative care.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.